Pyroptosis‐Amplified Decoy Nanovesicles Orchestrate Pyroptotic Antigen Explosion and Endogenous Immune Revitalization for Potentiating Tumour Immunotherapy
Authors:
Open Access
- 28 August 2026
- journal article
- research article
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (9) , e70356
Abstract
Current advances in tumour immunotherapy remain constrained by inadequate cytotoxic T lymphocyte activation and the immunosuppressive tumour microenvironment. Innovative strategies are urgently required to enhance anti‐tumour immune potency for clinical improvements in immunotherapy‐resistant malignancies. Herein, we developed pyroptosis‐amplified decoy nanovesicles (PADVs) to synergistically dismantle tumour resistance mechanisms and rejuvenate endogenous anti‐tumour immunity. PADVs integrate checkpoint‐neutralizing capability with precise regulation of the pyroptosis molecular switch in tumour cells, thereby initiating a sequential activation cascade that enables efficient presentation of tumour‐specific antigens to the reshaped immune system. Systemically infused PADVs demonstrated dual‐targeting priority towards lymph node and deep tumour tissues, reversing immunosuppression through competitive blockade of PD‐1/PD‐L1 and SIRPα/CD47 axes while providing co‐stimulatory signals for immune reactivation. Furthermore, PADVs alleviate the epigenetic suppression of pyroptosis in tumours via cytosolic delivery of decitabine and LPS, enabling gasdermin D (GSDMD) upregulation and cleavage. This coordinated strategy reverses T cell exhaustion and triggers explosive antigen release via GSDMD‐mediated membrane perforation, initiating a self‐amplifying immune cascade involving dendritic cell activation, effector and memory T cell formation. Consequently, PADVs demonstrate excellent efficacy in suppressing tumour progression, recurrence, and metastasis in melanoma, breast cancer, and colon cancer models. This study pioneers a versatile nanoplatform that not only counteracts tumour immune evasion but also establishes durable anti‐tumour immunity, offering a transformative approach to tumour immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82301027)
- National Natural Science Foundation of China (82170925)
- National Natural Science Foundation of China (82502730)
- National Natural Science Foundation of China (82201774)
- National Natural Science Foundation of China (32101096)
- National Natural Science Foundation of China (82402847)
- National Natural Science Foundation of China (U23A20453)
- China Postdoctoral Science Foundation (2023M734280)
- China Postdoctoral Science Foundation (2024M754265)
- China Postdoctoral Science Foundation (2024T171196)
- Fundamental Research Funds for the Central Universities (YD9110002019)
This publication has 26 references indexed in Scilit:
- Genetically Engineered Membrane‐Coated Nanoparticles for Enhanced Prostate‐Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration‐Resistant Prostate CancerAdvanced Science, 2024
- Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapyExploration, 2024
- Uptake of extracellular vesicles into immune cells is enhanced by the protein coronaJournal of Extracellular Vesicles, 2023
- Simultaneous Activation of Pyroptosis and cGAS‐STING Pathway with Epigenetic/ Photodynamic Nanotheranostic for Enhanced Tumor PhotoimmunotherapyAdvanced Materials, 2023
- The evolving tumor microenvironment: From cancer initiation to metastatic outgrowthCancer Cell, 2023
- Engineered Extracellular Vesicles with SHP2 High Expression Promote Mitophagy for Alzheimer's Disease TreatmentAdvanced Materials, 2022
- Recent advances in overcoming barriers to cell‐based delivery systems for cancer immunotherapyExploration, 2022
- Engineered Extracellular Vesicles for Cancer TherapyAdvanced Materials, 2021
- Biomimetic Nanotechnology toward Personalized VaccinesAdvanced Materials, 2019
- Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancerCancer Medicine, 2019